Incidence of Acute Ischemic Stroke in Hospitalized Patients With Atrial Fibrillation Who Had Anticoagulation Interruption: A Retrospective Study
- PMID: 34349863
- PMCID: PMC8297036
- DOI: 10.14740/cr1263
Incidence of Acute Ischemic Stroke in Hospitalized Patients With Atrial Fibrillation Who Had Anticoagulation Interruption: A Retrospective Study
Abstract
Background: Atrial fibrillation (AF) is one of the leading causes of acute ischemic stroke requiring anticoagulation. Many patients experience treatment interruption in the hospital setting. The aim of this study was to evaluate the effect of anticoagulation interruption on short-term risk of ischemic stroke in hospitalized patients with AF.
Methods: We performed a retrospective medical record review using the Hospital Corporation of America (HCA) database. We included patients admitted to our institution between December 2015 and December 2018 who had a prior history of AF. Patients were excluded if they had ischemic stroke, hemorrhagic stroke, history venous thromboembolism or mechanical valve on admission. We compared the incidence of ischemic stroke in patients in whom anticoagulation was interrupted for more than 48 h to those who continued anticoagulation.
Results: A total of 2,277 patients with history of AF were included in the study. In this cohort, 79 patients (3.47%) had anticoagulation interruption of more than 48 h during their hospital stay. There was no difference in incidence of stroke between the interruption and no interruption groups (1.27% (n = 1) vs. 0.23% (n = 5), P = 0.19). Interruption of anticoagulation did not associate with a significant increase in the risk of in-hospital ischemic stroke. CHA2DS2VASc score was a strong predictor of in-hospital stroke risk regardless of anticoagulation interruption (odds ratio: 7.199, 95% confidence interval: 2.920 - 17.751).
Conclusion: In this study, the in-hospital incidence of ischemic stroke in patients with AF did not significantly increase by short-term anticoagulation interruption.
Keywords: AF and stroke; Anticoagulation; Anticoagulation interruption; Atrial fibrillation; CHA2DS2VASc score; In-hospital stroke; Ischemic stroke.
Copyright 2021, Hasan et al.
Conflict of interest statement
None to declare.
Similar articles
-
Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial.Int J Cardiol. 2018 Apr 15;257:102-107. doi: 10.1016/j.ijcard.2018.01.065. Epub 2018 Feb 2. Int J Cardiol. 2018. PMID: 29395361 Clinical Trial.
-
Left Atrial Enlargement and Anticoagulation Status in Patients with Acute Ischemic Stroke and Atrial Fibrillation.J Stroke Cerebrovasc Dis. 2018 Jan;27(1):192-197. doi: 10.1016/j.jstrokecerebrovasdis.2017.08.025. Epub 2017 Sep 13. J Stroke Cerebrovasc Dis. 2018. PMID: 28918087
-
Impact of CHA2DS2VASc Score on Candidacy for Anticoagulation in Patients With Atrial Fibrillation: A Multi-payer Analysis.Clin Ther. 2016 Oct;38(10):2196-2203.e5. doi: 10.1016/j.clinthera.2016.08.011. Epub 2016 Sep 23. Clin Ther. 2016. PMID: 27671867
-
Burden of atrial fibrillation: a retrospective review of patients presenting to acute medical services.Intern Med J. 2016 Oct;46(10):1166-1171. doi: 10.1111/imj.13200. Intern Med J. 2016. PMID: 27501863
-
Perioperative Heparin Bridging in Atrial Fibrillation Patients Requiring Temporary Interruption of Anticoagulation: Evidence from Meta-analysis.J Stroke Cerebrovasc Dis. 2016 Sep;25(9):2215-21. doi: 10.1016/j.jstrokecerebrovasdis.2016.04.006. Epub 2016 Jun 8. J Stroke Cerebrovasc Dis. 2016. PMID: 27289185 Review.
References
LinkOut - more resources
Full Text Sources